Bianca Kizy, MD
Ophthalmology · Royal Oak, MINPI 1548655152
Payments from drug & device makers
Across 62 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$246
- Bausch & Lomb Americas Inc.$142
- Ocular Therapeutix, Inc.$141
- Tarsus Pharmaceuticals, Inc.$110
- Glaukos Corporation$104
- AbbVie$99
- plus $515 from 13 others
What the payments were for
- Food & beverage$1,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 13 | $246 |
| Bausch & Lomb Americas Inc. | 7 | $142 |
| Ocular Therapeutix, Inc. | 8 | $141 |
| Tarsus Pharmaceuticals, Inc. | 4 | $110 |
| Glaukos Corporation | 3 | $104 |
| AbbVie(2 entities) | 5 | $99 |
| Novartis | 3 | $67 |
| Harrow Eye, LLC | 2 | $66 |
| Rxsight Inc | 2 | $58 |
| Biotissue Holdings Inc. | 2 | $57 |
| Sun Pharmaceutical Industries Inc. | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Sight Sciences, Inc. | 2 | $36 |
| Amgen | 2 | $31 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| Dompe US, Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$1,355 in reported general payments places this provider in the 50th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 23 | $36,807 |
| XiidraLifitegrast | 15 | $16,542 |
| Prednisolone Acetate | 310 | $16,463 |
| LumiganBimatoprost | 35 | $16,184 |
| CombiganBrimonidine Tartrate/Timolol | 26 | $12,998 |
| MieboPerfluorohexyloctane/Pf | 16 | $11,802 |
| Latanoprost | 551 | $9,722 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $8,258 |
| Ketorolac Tromethamine | 315 | $4,914 |
| MoxifloxacinMoxifloxacin Hcl | 219 | $3,898 |
| Brimonidine Tartrate | 177 | $3,432 |
| ErythromycinErythromycin Base | 276 | $3,291 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 126 | $3,131 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $2,795 |
| Fluorometholone | 21 | $1,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $99 | $65,98984 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $142 | $28,34431 claims |
| AlconSimbrinza | $246 | $8,25820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Royal Oak
- Alan RubyRoyal Oak$35K
- Mahdi BashaFraser$2.2M
- Thomas WubbenAnn Arbor$1.2M
- Manjool ShahAnn Arbor$745K
- Scott WesthouseGrand Rapids$525K
- Gregory KatzYpsilanti$495K
- Cagri BesirliAnn Arbor$441K
- David BrownSaint Joseph$432K
- Vinay AakaluAnn Arbor$429K
- Timothy PageBirmingham$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.